Among these DH/TH-HGBL patients with BCL6 rearrangement, only six (37.5%) overexpressed MYC and BCL6 proteins simultaneously as shown by IHC staining, indicating the co-overexpression of MYC and BCL6 proteins may not be a plausible surrogate biomarker for screening BCL6-rearranged DH HGBL (Table 2). This evidence concerns the gene MYC and high grade B-cell lymphoma.